Alderuccio Frank, Chan James, Scott David W, Toh Ban-Hock
Department of Immunology, Nursing and Health Sciences, Monash University, Victoria 3181, Australia.
Trends Mol Med. 2009 Aug;15(8):344-51. doi: 10.1016/j.molmed.2009.06.002. Epub 2009 Aug 6.
Current treatment of human autoimmune disease by autologous bone marrow stem-cell transfer is hampered by frequent disease relapses. This is most probably owing to re-emergent self-reactive lymphocytes. Gene therapy combined with bone marrow stem cells has successfully introduced genes lacking in immunodeficiences. Because the bone marrow compartment has a key role in establishing immune tolerance, this combination strategy should offer a rational approach to prevent re-emergent self-reactive lymphocytes by establishing solid, life-long immune tolerance to causative self-antigen. Indeed, we have recently demonstrated the success of this combination approach to prevent and cure an experimental autoimmune disease. We suggest that this combination strategy has the potential for translation to treat human autoimmune diseases in which causative self-antigens are known.
自体骨髓干细胞移植目前在治疗人类自身免疫性疾病时,常因疾病频繁复发而受阻。这很可能是由于自身反应性淋巴细胞再次出现所致。基因治疗与骨髓干细胞相结合已成功地导入了免疫缺陷中所缺乏的基因。由于骨髓区室在建立免疫耐受方面起关键作用,这种联合策略应提供一种合理的方法,通过对致病性自身抗原建立稳固的、终身的免疫耐受来预防自身反应性淋巴细胞再次出现。事实上,我们最近已经证明了这种联合方法在预防和治疗实验性自身免疫性疾病方面的成功。我们认为,这种联合策略有潜力转化用于治疗已知致病性自身抗原的人类自身免疫性疾病。